vTv Therapeutics (FRA:5VT0) Inventories, Raw Materials & Components: €0.00 Mil (As of Mar. 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €31.40
GF Value €7,126.05
View Full Analysis

What is vTv Therapeutics Inventories, Raw Materials & Components?

vTv Therapeutics FRA:5VT0 +1.95% 35 Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €7,126.05.

vTv Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €0.00 Mil.

vTv Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Inventories, Raw Materials & Components Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €0.00 Mil mean?
vTv Therapeutics (FRA:5VT0) has a Inventories, Raw Materials & Components of €0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on vTv Therapeutics and its competitors.
Is vTv Therapeutics' Inventories, Raw Materials & Components too high?
vTv Therapeutics' current Inventories, Raw Materials & Components is €0.00 Mil. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Inventories, Raw Materials & Components compare to SMNR and CNTB?
vTv Therapeutics' Inventories, Raw Materials & Components of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current Inventories, Raw Materials & Components is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Inventories, Raw Materials & Components of €0.00 Mil. The stock's GF Value™ is €7,126.05, compared to a current price of €31.40 — trading 99.6% below its estimated fair value. The current Inventories, Raw Materials & Components is €0.00 Mil. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €31.40 is trading 99.6% below its estimated GF Value™ of €7,126.05.

Key valuation signals for FRA:5VT0:

  • Inventories, Raw Materials & Components: €0.00 Mil
  • GF Value™: €7,126.05 vs. price of €31.40 (99.6% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.40
Price
€7,126.05
GF Value